checkAd
    Startseite > Aktien > Agenus > Nachrichten
    Agenus Aktie
    11,690
     
    USD
    +40,84 %
    +3,390 USD
    Letzter Kurs 02:00:00 Nasdaq
    11,680
     
    USD
    3.800 STK
    Geldkurs 26.04.24
    11,690
     
    USD
    600 STK
    Briefkurs 26.04.24
    ISIN: US00847G8042 · WKN: A403RK · SYM: AGEN · USA

    Neueste Nachrichten

    Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
    24.04.24 · Business Wire (engl.) · Agenus
    Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
    23.04.24 · Business Wire (engl.) · Agenus
    Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
    12.04.24 · Business Wire (engl.) · Agenus
    Agenus Announces Reverse Stock Split of Common Stock
    05.04.24 · Business Wire (engl.) · Agenus
    Agenus Reports Fourth Quarter and Full Year 2023 Results
    14.03.24 · Business Wire (engl.) · Agenus
    Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
    06.03.24 · Business Wire (engl.) · Agenus
    Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    05.03.24 · Business Wire (engl.) · Agenus
    Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
    29.02.24 · Business Wire (engl.) · Agenus
    Agenus to Participate in Leerink Partners Global Biopharma Conference
    26.02.24 · Business Wire (engl.) · Agenus
    Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
    31.01.24 · Business Wire (engl.) · Agenus
    Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population
    22.01.24 · Business Wire (engl.) · Agenus
    Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    05.01.24 · Business Wire (engl.) · Agenus